The Pharma Letter Podcast — Episode 13 — Is there a data capture crisis in biotech?
More on this story...
Today's issue
Company Spotlight
A Boulder, Colorado-based biotech that has sharpened its focus entirely on cardiovascular disease after divesting its muscular dystrophy franchise to Servier, with oral cardiac sarcomere modulator EDG-7500 now its singular Phase III-bound bet in hypertrophic cardiomyopathy.
More Features in Biotechnology
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze